Abstract：
While the clinical benefits of terlipressin (TP) have been reported in adults and children with refractory hypotension, data in neonates are limited.
Herein, we report a case of off-label rescue TP therapy in a neonate with septic shock and persistent hypotension. The patient`s blood pressure was normalized, and tissue perfusion improved without serious adverse reactions. However, genetic testing revealed mitochondrial gene defects in the patient, and the parents subsequently elected to stop treatment after 25 doses of TP (20 μg/kg/min every 4 h for 100 h).
While TP treatment appeared to help control hypotension and may prolong the survival time, there are no conclusive data regarding the safety and efficacy of TP in neonates.
Herein, we report a case of off-label rescue TP therapy in a neonate with septic shock and persistent hypotension. The patient`s blood pressure was normalized, and tissue perfusion improved without serious adverse reactions. However, genetic testing revealed mitochondrial gene defects in the patient, and the parents subsequently elected to stop treatment after 25 doses of TP (20 μg/kg/min every 4 h for 100 h).
While TP treatment appeared to help control hypotension and may prolong the survival time, there are no conclusive data regarding the safety and efficacy of TP in neonates.
摘要：
虽然已经报道了特利加压素（TP）在患有难治性低血压的成人和儿童中的临床益处，新生儿的数据有限。
这里，我们报道1例新生儿感染性休克和持续性低血压的超说明书抢救TP治疗.病人的血压恢复正常,组织灌注改善，无严重不良反应。然而,基因检测显示患者的线粒体基因缺陷,父母随后选择在25剂TP（每4小时20μg/kg/min，持续100小时）后停止治疗。
虽然TP治疗似乎有助于控制低血压并可能延长生存时间，目前尚无关于新生儿TP安全性和有效性的结论性数据.
这里，我们报道1例新生儿感染性休克和持续性低血压的超说明书抢救TP治疗.病人的血压恢复正常,组织灌注改善，无严重不良反应。然而,基因检测显示患者的线粒体基因缺陷,父母随后选择在25剂TP（每4小时20μg/kg/min，持续100小时）后停止治疗。
虽然TP治疗似乎有助于控制低血压并可能延长生存时间，目前尚无关于新生儿TP安全性和有效性的结论性数据.
